AU2022316200A1 - Compositions and methods for inhibiting creatine transport as a treatment for cancer - Google Patents

Compositions and methods for inhibiting creatine transport as a treatment for cancer Download PDF

Info

Publication number
AU2022316200A1
AU2022316200A1 AU2022316200A AU2022316200A AU2022316200A1 AU 2022316200 A1 AU2022316200 A1 AU 2022316200A1 AU 2022316200 A AU2022316200 A AU 2022316200A AU 2022316200 A AU2022316200 A AU 2022316200A AU 2022316200 A1 AU2022316200 A1 AU 2022316200A1
Authority
AU
Australia
Prior art keywords
cancer
creatine
rgx
kras
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022316200A
Other languages
English (en)
Inventor
David DARST
Isabel KURTH
Masoud TAVAZOIE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inspirna Inc
Original Assignee
Inspirna Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inspirna Inc filed Critical Inspirna Inc
Publication of AU2022316200A1 publication Critical patent/AU2022316200A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2022316200A 2021-07-20 2022-07-19 Compositions and methods for inhibiting creatine transport as a treatment for cancer Pending AU2022316200A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163223926P 2021-07-20 2021-07-20
US63/223,926 2021-07-20
PCT/US2022/073884 WO2023004308A1 (en) 2021-07-20 2022-07-19 Compositions and methods for inhibiting creatine transport as a treatment for cancer

Publications (1)

Publication Number Publication Date
AU2022316200A1 true AU2022316200A1 (en) 2024-01-25

Family

ID=84979767

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022316200A Pending AU2022316200A1 (en) 2021-07-20 2022-07-19 Compositions and methods for inhibiting creatine transport as a treatment for cancer

Country Status (6)

Country Link
US (1) US20240180912A1 (https=)
EP (1) EP4373582A4 (https=)
JP (1) JP2024528705A (https=)
AU (1) AU2022316200A1 (https=)
CA (1) CA3225305A1 (https=)
WO (1) WO2023004308A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119522225A (zh) 2022-09-29 2025-02-25 广州嘉越医药科技有限公司 大环衍生物及其应用
CN116602948B (zh) * 2023-06-06 2024-12-06 湖南岳靶生物医药有限公司 一种可用于降低膀胱癌细胞耐药性的化合物、组合物及其应用
WO2025114580A1 (en) * 2023-11-30 2025-06-05 National And Kapodistrian University Of Athens N-aminoguanidine derivatives with anticancer activity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3736022A3 (en) * 2012-10-31 2021-01-20 The Rockefeller University Treatment and diagnosis of colon cancer
US20180002702A1 (en) * 2014-12-26 2018-01-04 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
WO2021062157A1 (en) * 2019-09-27 2021-04-01 The Rockefeller University Compositions and methods for treating metastatic gastrointestinal cancer
UA128683C2 (uk) * 2019-10-22 2024-09-25 Люпін Лімітед Фармацевтична комбінація на основі інгібіторів prmt5
JP2023505687A (ja) * 2019-12-11 2023-02-10 インスピルナ，インコーポレーテッド 癌の処置方法

Also Published As

Publication number Publication date
EP4373582A1 (en) 2024-05-29
US20240180912A1 (en) 2024-06-06
WO2023004308A1 (en) 2023-01-26
CA3225305A1 (en) 2023-01-26
EP4373582A4 (en) 2025-11-05
JP2024528705A (ja) 2024-07-30

Similar Documents

Publication Publication Date Title
US20240366567A1 (en) Pharmaceutical combinations comprising a kras g12c inhibitor and uses thereof for the treatment of cancers
Shapiro et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors
AU2018288060B2 (en) IL-1beta binding antibodies for use in treating cancer
AU2022316200A1 (en) Compositions and methods for inhibiting creatine transport as a treatment for cancer
US20210290620A1 (en) Combinations of RET Inhibitors and mTORC1 Inhibitors and Uses Thereof for the Treatment of Cancer Mediated by Aberrant RET Activity
TW201032796A (en) Treatment of lung cancer with a PARP inhibitor in combination with a growth factor inhibitor
Traynor et al. Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors
JP2023145689A (ja) Ｈｅｒ２陽性がんの処置
CA2909290A1 (en) Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
US10220091B2 (en) Combination treatments with sonic hedgehog inhibitors
Konar et al. Synthesis and clinical development of palbociclib: An overview
CN108472376A (zh) 用于治疗癌症的合理组合疗法
JP7571024B2 (ja) 抗ｃｃｒ４抗体抵抗性のがんの治療剤
WO2018235056A1 (en) Il-1beta binding antibodies for use in treating cancer
US20150306216A1 (en) Combinations of a pi3k/akt inhibitor compound with an her3/egfr inhibitor compound and use thereof in the treatment of a hyperproliferative disorder
Khalifa PERIODIC FASTING AS A TOOL FOR DRUG REPURPOSING: ENHANCEMENT OF CHOLESTEROL BIOSYNTHESIS INHIBITORS ANTITUMOR EFFECTS VIA DIETARY RESTRICTION
CN121620372A (zh) Plk1抑制剂对缺氧信号传导途径的抑制作用